The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy.

ATOR-1015 is designed with properties that shall enable it to accumulate in the tumor area after an intravenous injection, and selectively exert its effect there, states the company in their press release.

Results are expected in the second half of 2020

The study, being initiated in five different clinics across Sweden and Denmark, is a first-in-human dose-escalation study in up to 53 patients with advanced solid tumor disease. The primary aim of the study is to investigate the safety and tolerability of the drug and to identify the recommended dose for subsequent phase II studies. The results of the study are expected to read out in the second half of 2020.

“I state with satisfaction that ATOR-1015 is the first investigational tumor-localizing bispecific CTLA-4 antibody ever being tested in the clinic. With this, Alligator takes the lead in a very hot area of research. While immune activation through CTLA-4 has shown impressive efficacy in multiple cancers, it is coupled with severe toxicity. We believe that ATOR-1015 will be at least as effective as the approved monospecific CTLA-4 antibody Yervoy, and with less side effects,” said Per Norlén, CEO of Alligator. “As the study progresses we look forward to learning more about the potential of this investigational medicine to improve the treatment of multiple cancers”.

Read also:

A paradigm-shift in cancer?

GSK acquires Merck’s cancer immunotherapy for up to €3.7 billion